GO:2000669 negative regulation of dendritic cell apoptotic process: Immune Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000669 describes any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell apoptotic process.
• Dendritic cell apoptosis is a key regulatory mechanism that limits immune responses and maintains tolerance.
• Negative regulation of dendritic cell apoptosis is essential for sustaining antigen presentation and T cell activation during infection and cancer.
• Key molecular players include A20 (TNFAIP3), PD-1/PD-L1 signaling, SLC7A11, and metabolic regulators such as Akt2.
• Dysregulation of this process contributes to autoimmunity, chronic inflammation, and tumor immune evasion.
• CRISPR knockout, knock-in, and overexpression models enable precise dissection of genes controlling dendritic cell survival.
Description
Dendritic cells (DCs) are professional antigen-presenting cells that bridge innate and adaptive immunity. Their lifespan and survival are tightly controlled by programmed cell death, and the negative regulation of dendritic cell apoptotic process (GO:2000669) refers to any mechanism that inhibits or delays DC apoptosis. This regulation is critical for mounting effective immune responses while preventing excessive inflammation or autoimmunity. The term encompasses signaling pathways, anti-apoptotic proteins, and metabolic checkpoints that promote DC survival under specific conditions. Understanding GO:2000669 is essential for researchers studying immune tolerance, vaccine design, cancer immunotherapy, and autoimmune diseases. This article integrates authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to this process.
negative regulation of dendritic cell apoptotic process At A Glance
| GO ID | GO:2000669 |
|---|---|
| GO term | negative regulation of dendritic cell apoptotic process |
| Ontology | biological_process |
| Synonym | negative regulation of dendritic cell apoptosis |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell apoptotic process. |
| Major function | Promotes dendritic cell survival and sustained immune responses |
| Related processes | Apoptosis, immune regulation, cytokine signaling |
| Key regulators | A20, PD-1/PD-L1, SLC7A11, Akt2 |
What Is GO:2000669?
GO:2000669, negative regulation of dendritic cell apoptotic process, is defined as any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell apoptotic process. In other words, it includes molecular events that prolong dendritic cell survival by blocking apoptosis. This biological process is distinct from general cell survival because it specifically targets the apoptotic machinery in dendritic cells, a specialized immune cell type.
Why Is negative regulation of dendritic cell apoptotic process Important in Cell Biology?
The negative regulation of dendritic cell apoptotic process is central to immune homeostasis because dendritic cells are essential for initiating T cell responses and maintaining tolerance. If DCs undergo apoptosis prematurely, immune responses may be impaired, leading to susceptibility to infections or cancer. Conversely, excessive DC survival can drive chronic inflammation and autoimmunity. Therefore, understanding GO:2000669 provides insights into how the immune system balances activation and resolution, and it offers therapeutic targets for diseases ranging from cancer to diabetes.
• Sustains antigen presentation and T cell priming during infection.
• Prevents premature loss of dendritic cells in cancer immunotherapy.
• Contributes to immune tolerance and prevention of autoimmunity.
• Regulates wound healing and tissue repair through efferocytosis.
• Involved in metabolic disorders such as diabetes via SLC7A11.
• Modulated by co-inhibitory pathways like PD-1/PD-L1.
• Affected by high glucose and Akt2 signaling in DCs.
• Target for improving vaccine efficacy and duration of immune response.
• Dysregulated in chemobrain and neuroinflammation.
• Key for understanding immune evasion in tumor microenvironments.
What Happens During negative regulation of dendritic cell apoptotic process?
Initiation of survival signaling
In simple terms: Survival signals turn on inside the dendritic cell to block death.
Negative regulation of dendritic cell apoptosis begins when extracellular or intracellular cues activate anti-apoptotic pathways. For example, engagement of PD-1 by its ligand B7-H1 (PD-L1) delivers inhibitory signals that can modulate lymphocyte activation, and similar co-inhibitory pathways influence DC survival. Additionally, high glucose conditions can activate Akt2 signaling, which promotes DC survival through A20-dependent mechanisms.
Inhibition of apoptotic machinery
In simple terms: The cell blocks the proteins that would normally cause it to die.
Once survival signaling is initiated, downstream effectors inhibit pro-apoptotic proteins such as caspases and Bcl-2 family members. A20 (TNFAIP3) is a key negative regulator of NF-kB signaling and can protect DCs from apoptosis under stress conditions. The precise molecular interactions often involve ubiquitin editing and kinase cascades that shift the balance toward cell survival.
Metabolic support for survival
In simple terms: The cell adjusts its metabolism to stay alive.
Metabolic reprogramming supports DC survival. SLC7A11, a cystine/glutamate antiporter, plays a role in redox balance and efferocytosis; targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes, indicating that metabolic pathways can influence DC lifespan and function. Disulfidptosis nanoinducers can interrupt tumor metabolic privilege and boost immunotherapy, suggesting that metabolic stress can override survival signals.
Integration with immune regulation
In simple terms: Survival decisions are linked to the overall immune response.
The negative regulation of DC apoptosis is tightly integrated with immune regulation. Programmed cell death of dendritic cells is a critical mechanism in immune regulation, and its inhibition can prolong antigen presentation and enhance T cell responses. Conversely, dysregulated survival may contribute to autoimmune reactions.
Key Genes Involved in GO:2000669 negative regulation of dendritic cell apoptotic process
The following genes and proteins have been experimentally linked to the regulation of dendritic cell apoptosis or survival, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFAIP3 (A20) | Inhibits NF-kB signaling and protects DCs from apoptosis | High glucose-induced Akt2 signaling regulates DC function via A20 |
| PDCD1 (PD-1) | Co-inhibitory receptor that modulates lymphocyte activation | Engagement of PD-1 by B7 family member leads to negative regulation of lymphocyte activation |
| SLC7A11 | Cystine/glutamate antiporter involved in redox balance | Targeting SLC7A11 improves efferocytosis by DCs and wound healing in diabetes |
| AKT2 | Serine/threonine kinase mediating survival signals | Regulates DC function through A20 under high glucose |
| MAST1 | Microtubule-associated serine/threonine kinase | Mutations cause mega-corpus-callosum syndrome; may affect neuronal and immune cells |
| NKG2D | Activating receptor on NK and T cells | Enhances double-negative T cell regulation of B cells; may influence DC interactions |
| B7-H1 (PD-L1) | Ligand for PD-1, delivers inhibitory signals | Engagement of PD-1 by B7-H1 leads to negative regulation of lymphocyte activation |
| CASP3 | Executioner caspase in apoptosis | General apoptotic machinery; its inhibition is a hallmark of negative regulation of apoptosis |
| BCL2 | Anti-apoptotic protein | Overexpression promotes cell survival; relevant to DC survival |
| BAX | Pro-apoptotic protein | Its inhibition contributes to negative regulation of apoptosis |
| NFKB1 | Transcription factor in survival signaling | A20 modulates NF-kB; affects DC survival |
| MAPK1 | Kinase in survival pathways | Downstream of Akt2; may influence DC apoptosis |
| MTOR | Central regulator of cell growth and survival | Metformin affects chemobrain via cellular pathways including mTOR |
| SLC3A2 | Partner of SLC7A11 in cystine transport | Involved in metabolic regulation of DC function |
| GCLC | Glutamate-cysteine ligase, glutathione synthesis | Redox balance affects DC survival |
| TXN | Thioredoxin, antioxidant | Protects cells from oxidative stress-induced apoptosis |
| CASP8 | Initiator caspase in extrinsic apoptosis | Its inhibition blocks apoptosis in DCs |
| FAS | Death receptor | Fas-mediated apoptosis is a key pathway in DC death |
How Is negative regulation of dendritic cell apoptotic process Regulated?
The negative regulation of dendritic cell apoptotic process is controlled by multiple signaling pathways. The PD-1/PD-L1 axis delivers inhibitory signals that can modulate lymphocyte activation and potentially DC survival. A20 (TNFAIP3) acts as a negative regulator of NF-kB and is itself regulated by Akt2 under high glucose conditions. Metabolic regulators such as SLC7A11 influence redox balance and efferocytosis, thereby affecting DC lifespan. Additionally, metformin, an AMPK activator, has been shown to affect chemobrain through cellular pathways that may include mTOR and apoptosis regulation. These layers of regulation ensure that DC survival is tightly coupled to environmental cues and immune demands.
negative regulation of dendritic cell apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A11 | Diabetes, impaired wound healing | Knockout mice or DC-specific deletion; efferocytosis assays |
| TNFAIP3 (A20) | Autoimmunity, inflammation | Point mutation or knockout in DCs; high glucose stimulation |
| PDCD1 (PD-1) | Cancer, autoimmunity | Knockout mice; PD-1/PD-L1 blockade models |
| MAST1 | Mega-corpus-callosum syndrome | Knock-in of patient mutations; neuronal and immune cell studies |
| NKG2D | Autoimmune B cell regulation | Knockout or overexpression in T cell subsets |
Cancer and tumor immunity
In cancer, dendritic cells often exhibit impaired survival, which limits anti-tumor immunity. Negative regulation of DC apoptosis can enhance antigen presentation and improve immunotherapy outcomes. Disulfidptosis nanoinducers that interrupt tumor metabolic privilege boost sustained immunotherapy, partly by modulating DC survival. Targeting pathways that promote DC survival may therefore synergize with immune checkpoint blockade.
Diabetes and wound healing
Diabetes is associated with impaired wound healing and chronic inflammation. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes, indicating that metabolic control of DC survival and function is critical in this disease. High glucose conditions can also dysregulate Akt2/A20 signaling in DCs, potentially altering their lifespan.
Autoimmunity and chronic inflammation
Excessive dendritic cell survival can perpetuate autoimmune responses. Programmed cell death of dendritic cells is a key mechanism in immune regulation, and its failure may contribute to autoimmunity. Modulating the negative regulation of DC apoptosis could therefore be a therapeutic strategy for autoimmune diseases.
Neurological disorders and chemobrain
Chemotherapy-induced cognitive impairment (chemobrain) involves neuroinflammation and immune dysregulation. Metformin has been investigated for its effects on chemobrain from cells to bedside, with pathways that may intersect with dendritic cell survival and apoptosis. Understanding DC apoptosis regulation in the brain may reveal new targets for neuroprotection.
From negative regulation of dendritic cell apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X inhibit dendritic cell apoptosis? | CRISPR knockout of gene X in DC cell lines or primary DCs, followed by apoptosis assays |
| Does a specific point mutation in A20 affect DC survival? | Point-mutation knock-in using CRISPR in DCs, then high glucose challenge |
| Can overexpression of SLC7A11 prolong DC survival? | Overexpression of SLC7A11 in DCs, measure efferocytosis and apoptosis |
| What is the role of PD-1 in DC survival? | PD-1 knockout mice or DC-specific PD-1 deletion, assess DC apoptosis |
| Does MAST1 mutation alter DC apoptosis? | Knock-in of MAST1 mutations in DCs, measure survival and signaling |
| Can metabolic modulators affect DC apoptosis? | Treatment with metformin or disulfidptosis inducers in DC cultures |
How to Study the negative regulation of dendritic cell apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Annexin V/PI flow cytometry | Apoptosis and necrosis | Quantify DC death after gene knockout |
| Caspase-3/7 activity assay | Caspase activation | Confirm apoptotic pathway involvement |
| CRISPR knockout screen | Gene essentiality for survival | Identify negative regulators of DC apoptosis |
| RNA-seq | Transcriptional changes | Profile survival pathways after perturbation |
| Western blot | Protein expression and cleavage | Detect A20, Akt2, caspase cleavage |
| Glutathione assay | Redox status | Assess SLC7A11 function in DCs |
| Efferocytosis assay | Clearance of apoptotic cells | Measure DC function in diabetes models |
| Live-cell imaging | Real-time survival dynamics | Track DC apoptosis over time |
Apoptosis assays
Annexin V/PI staining, caspase activity assays, and TUNEL staining are standard methods to quantify dendritic cell apoptosis. These assays can be used to assess the effect of genetic perturbations or drug treatments on DC survival.
Genetic screens and CRISPR libraries
CRISPR knockout libraries enable unbiased discovery of genes that negatively regulate DC apoptosis. Pooled screens with next-generation sequencing can identify survival genes under specific stress conditions.
Flow cytometry and imaging
Flow cytometry allows immunophenotyping of DCs and simultaneous assessment of apoptosis markers. Live-cell imaging can track survival dynamics in real time.
Metabolic and redox assays
Measurements of glutathione, reactive oxygen species, and cystine uptake are relevant for studying SLC7A11 and metabolic regulation of DC survival.
How CRISPR Can Be Used to Study GO:2000669 negative regulation of dendritic cell apoptotic process
Knockout
CRISPR knockout of candidate genes such as TNFAIP3 or SLC7A11 in dendritic cells can reveal their role in negative regulation of apoptosis. For example, A20 knockout may sensitize DCs to apoptosis under high glucose, while SLC7A11 knockout may impair efferocytosis.
Point Mutation
Point mutations can mimic disease-associated variants. For instance, MAST1 mutations found in mega-corpus-callosum syndrome can be introduced into DCs to study their effect on survival. Similarly, phospho-mutants of Akt2 can dissect signaling.
Knock-in
Knock-in of tagged proteins (e.g., GFP-A20) allows visualization of protein localization and dynamics during DC apoptosis. This approach helps track survival factors in real time.
Overexpression
Overexpression of anti-apoptotic genes such as BCL2 or SLC7A11 can protect DCs from apoptosis, providing gain-of-function evidence. This is useful for validating therapeutic targets.
How EDITGENE Supports negative regulation of dendritic cell apoptotic process Research
Researchers studying negative regulation of dendritic cell apoptotic process-related genes often need to determine whether a candidate gene is causally involved in DC survival. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of dendritic cell apoptotic process research.
Frequently Asked Questions About negative regulation of dendritic cell apoptotic process
What is negative regulation of dendritic cell apoptotic process?
It is a biological process (GO:2000669) that stops, prevents or reduces the frequency, rate or extent of apoptosis in dendritic cells, thereby promoting their survival.
What genes are involved in negative regulation of dendritic cell apoptosis?
Key genes include TNFAIP3 (A20), PDCD1 (PD-1), SLC7A11, AKT2, and BCL2, among others.
How does PD-1 signaling affect dendritic cell survival?
Engagement of PD-1 by B7-H1 (PD-L1) delivers inhibitory signals that can modulate lymphocyte activation and may influence DC survival.
What is the role of A20 in dendritic cell apoptosis?
A20 (TNFAIP3) inhibits NF-kB signaling and protects dendritic cells from apoptosis, particularly under high glucose conditions via Akt2.
Can SLC7A11 regulate dendritic cell apoptosis?
SLC7A11 influences redox balance and efferocytosis; targeting it improves DC function in diabetes, suggesting a role in survival.
How is dendritic cell apoptosis studied experimentally?
Common methods include Annexin V/PI staining, caspase assays, CRISPR knockout screens, and flow cytometry.
What diseases are linked to defective dendritic cell apoptosis regulation?
Cancer, diabetes, autoimmunity, and neurological disorders like chemobrain have been associated with altered DC survival.
What CRISPR models are available for studying this process?
Knockout, point mutation, knock-in, and overexpression models in dendritic cell lines or primary cells are available from EDITGENE.
How does metformin affect dendritic cell apoptosis?
Metformin has been investigated for chemobrain and may affect cellular pathways including apoptosis and mTOR signaling.
Why is negative regulation of dendritic cell apoptosis important for immunotherapy?
Prolonging DC survival can enhance antigen presentation and T cell activation, improving anti-tumor immunity.
Conclusion
The negative regulation of dendritic cell apoptotic process (GO:2000669) is a critical immune regulatory mechanism that controls dendritic cell lifespan and function. Dysregulation of this process contributes to cancer, autoimmunity, diabetes, and neurological disorders. Advances in CRISPR gene editing and high-throughput screening are enabling precise dissection of the genes and pathways involved. EDITGENE provides comprehensive services to support these investigations, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Freeman GJ et al.. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.. J Exp Med 192(7):1027-34 PMID: 11015443
- 2. Leddy E et al.. 2025. Investigating the effect of metformin on chemobrain: Reports from cells to bedside.. Exp Neurol 385:115129 PMID: 39733854
- 3. Maschalidi S et al.. 2022. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes.. Nature 606(7915):776-784 PMID: 35614212
- 4. Xu Y et al.. 2025. Disulfidptosis Nanoinducer Interrupts Tumor Metabolic Privilege to Boost Sustained Immunotherapy.. ACS Nano 19(33):30303-30321 PMID: 40788631
- 5. Hu SH et al.. 2021. NKG2D Enhances Double-Negative T Cell Regulation of B Cells.. Front Immunol 12:650788 PMID: 34220808
- 6. Xuan NT et al.. 2019. Regulation of dendritic cell function by A20 through high glucose-induced Akt2 signaling.. J Recept Signal Transduct Res 39(5-6):434-441 PMID: 31755338
- 7. Chen M et al.. 2010. Programmed cell death of dendritic cells in immune regulation.. Immunol Rev 236:11-27 PMID: 20636805
- 8. Tripathy R et al.. 2018. Mutations in MAST1 Cause Mega-Corpus-Callosum Syndrome with Cerebellar Hypoplasia and Cortical Malformations.. Neuron 100(6):1354-1368.e5 PMID: 30449657
